Microplastics and Misinformation: What Science Really Says
November 12, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Surmontil, Tripramine, Trimip
Synonyms :
Class :
Antidepressants and antianxiety drugs; norepinephrine reuptake inhibitors
Brand Name :
Surmontil, Tripramine, Trimip
Synonyms :
Class :
Antidepressants and antianxiety drugs; norepinephrine reuptake inhibitors
Dosage forms & Strengths:Â
Adult:Â
Capsule:Â
25 mgÂ
50 mgÂ
100 mgÂ
They may increase the vasopressor effect when combined with Alpha-/Beta-Agonists
They may increase the vasopressor effect when combined with Alpha-/Beta-Agonists
They may increase the vasopressor effect when combined with Alpha-/Beta-Agonists
They may increase the vasopressor effect when combined with Alpha-/Beta-Agonists
They may increase the vasopressor effect when combined with Alpha-/Beta-Agonists
when both drugs are combined, there may be an increase in qtc interval  
may increase the CNS depressant effect of CNS depressants
may enhance the risk of CNS depression when combined with each other
may enhance the risk of CNS depression when combined with each other
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may have an increased Effect of CNS depressant when combined with serotonergic anorectic drugs
it increases the effect of CNS depressants
it increases the toxicity of norepinephrine reuptake inhibitors
it increases the effect of serotonergic agents
Norepinephrine Reuptake Inhibitors increase arrhythmia, causing the effect of dronedarone
anticholinergic agents decrease the efficacy of levosulpride
it increases the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
anticholinergic agents increase the ulcer-producing effect of potassium citrate
CNS depressants increase the CNS suppression effect of thalidomide
it increases the effect of Norepinephrine Reuptake Inhibitors
It may enhance QTc interval when combined with perphenazine
may increase the serotonergic effect of Monoamine Oxidase Inhibitors
CNS depressants increase the CNS depressing effect of brexanolone
it increases the concentration of Norepinephrine Reuptake Inhibitors
it increases the toxicity of Norepinephrine Reuptake Inhibitors
norepinephrine reuptake inhibitors decrease the effect of guanethidine
it increases the effect of CNS depressants
it increases the toxicity of serotonergic agents
it increases the effect of CNS depressants
anticholinergic agents increase the toxicity of topiramate
may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents
may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents
may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents
may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents
may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of Quinolone antibiotics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of Quinolone antibiotics
may increase the vasopressor effect
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may enhance the cholinergic blocking effect of other tricyclic antidepressants
may enhance the cholinergic blocking effect of other tricyclic antidepressants
may enhance the cholinergic blocking effect of other tricyclic antidepressants
tricyclic antidepressants: they may increase the toxic effect of Beta2-Agonists
tricyclic antidepressants: they may increase the toxic effect of Beta2-Agonists
tricyclic antidepressants: they may increase the toxic effect of Beta2-Agonists
tricyclic antidepressants: they may increase the toxic effect of Beta2-Agonists
tricyclic antidepressants: they may increase the toxic effect of Beta2-Agonists
tricyclic antidepressants: they may increase the toxic effect of Nonsteroidal Anti-Inflammatory Agents
tricyclic antidepressants: they may increase the toxic effect of Nonsteroidal Anti-Inflammatory Agents
tricyclic antidepressants: they may increase the toxic effect of Nonsteroidal Anti-Inflammatory Agents
tricyclic antidepressants: they may increase the toxic effect of Nonsteroidal Anti-Inflammatory Agents
tricyclic antidepressants: they may increase the toxic effect of Nonsteroidal Anti-Inflammatory Agents
When bufexamac is used together with trimipramine, this leads to enhanced risk or seriousness of gastrointestinal bleeding
trimipramine: they may enhance the serum concentration of CYP2D6 Inhibitors
trimipramine: they may enhance the serum concentration of CYP2D6 Inhibitors
trimipramine: they may enhance the serum concentration of CYP2D6 Inhibitors
trimipramine: they may enhance the serum concentration of CYP2D6 Inhibitors
trimipramine: they may enhance the serum concentration of CYP2D6 Inhibitors
combining trimipramine with isoxicam may increase the risk or severity of gastrointestinal bleeding
the risk of adverse effects may be elevated when rimonabant is combined with trimipramine
When trimipramine is used together with flunoxaprofen, this leads to enhanced risk or seriousness of gastrointestinal bleeding
may have an increased therapeutic effect when combined with alpha1-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
when both drugs are combined, there may be an increased risk or severity of QTC prolongation  
when used together, entrectinib and trimipramine both increase the QTc interval
osimertinib and trimipramine, when used simultaneously, increase the QTc interval
may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents
may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents
may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents
may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents
may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may enhance the arrhythmogenic effect
may enhance the arrhythmogenic effect
may enhance the arrhythmogenic effect
may enhance the arrhythmogenic effect
may enhance the cholinergic blocking effect of other tricyclic antidepressants
may enhance the cholinergic blocking effect of other tricyclic antidepressants
may enhance the cholinergic blocking effect of other tricyclic antidepressants
may enhance the cholinergic blocking effect of other tricyclic antidepressants
the risk of gastrointestinal bleeding may be increased
the serum levels of trimipramine may be increased
the CNS depression severity may be increased when trimipramine is combined with tubocurarine
the risk of gastrointestinal bleeding may be reduced
may enhance the severity of gastrointestinal bleeding when combined
may enhance the severity of gastrointestinal bleeding when combined
may enhance the severity of gastrointestinal bleeding when combined
may enhance the severity of gastrointestinal bleeding when combined
may enhance the severity of gastrointestinal bleeding when combined
they increase the metabolism of norepinephrine reuptake inhibitors
anticholinergic agents increase the effect of constipation of clozapine
it increases the effect of CNS depressants
it increases the effect of CNS depressants
CNS depressants increase the effect of opioid agonists
it increases the effect of norepinephrine reuptake inhibitors
anticholinergic agents decrease the efficacy of secretin
CNS depressants increase the effect of zolpidem
it increases the toxicity of atropine through an unknown mechanism
Frequency undefined:Â
SedationÂ
FatigueÂ
Dry mouthÂ
Blurred visionÂ
WeaknessÂ
LethargyÂ
HeadacheÂ
AgitationÂ
InsomniaÂ
NauseaÂ
VomitingÂ
AnxietyÂ
SweatingÂ
ConfusionÂ
EPSÂ
DizzinessÂ
TinnitusÂ
ParesthesiaÂ
Orthostatic hypotensionÂ
ECG changesÂ
TachycardiaÂ
Incr LFTsÂ
Sexual dysfunctionÂ
RashÂ
SeizureÂ
Trimipramine is contraindicated in patients hypersensitive to the formulation’s active ingredient and other excipients.Â
Pregnancy consideration:Â Â
Category C.Â
Breastfeeding warnings:Â Â
Avoid lactation during the treatment of trimipramine.Â
Pregnancy category:Â
Â
Patient information leafletÂ
Generic Name:Â trimipramineÂ
Pronounced: tri-mi-prah-mineÂ
Why do we use trimipramine?Â
Trimipramine treats depression.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
